Summary

Eligibility
for people ages 21-55 (full criteria)
Healthy Volunteers
healthy people welcome
Dates
study started
completion around
Principal Investigator
by Ziva Cooper, PhD (ucla)
Headshot of Ziva Cooper
Ziva Cooper

Description

Summary

The purpose of this research is to assess the impact of CBD on the effects of THC.

Official Title

Interactions Between Delta-9-THC and CBD: a Controlled Human Drug-administration Study Probing a Harm Reduction Strategy

Details

Some evidence indicates that cannabidiol (CBD), a non-intoxicating cannabis component, might mitigate certain effects of THC. This study will examine possible roles for CBD in modulating THC's adverse and analgesic effects.

Keywords

Abuse, Drug, Pain, Cannabis, THC, CBD, Substance-Related Disorders, CBD 20 mg, CBD 40 mg, CBD 80 mg

Eligibility

You can join if…

Open to people ages 21-55

  • Male or non-pregnant and non-lactating females aged 21-55 years
  • Report cannabis use 1-7 days per week over the month prior to screening
  • Not currently seeking treatment for their cannabis use
  • History of inhaled cannabis use
  • Have a Body Mass Index from 18.5 - 34 kg/m2
  • Able to perform all study procedures
  • Must be using a contraceptive (hormonal or barrier methods)

You CAN'T join if...

  • Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
  • Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
  • Report using other illicit drugs in the prior 4 weeks
  • Current pain
  • Pregnancy
  • Currently enrolled in another research protocol
  • Not using a contraceptive method (hormonal or barrier methods)
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
  • Not able to speak and read English

Lead Scientist at University of California Health

  • Ziva Cooper, PhD (ucla)
    Dr. Ziva Cooper, Ph.D. is the Director of the UCLA Center for Cannabis and Cannabinoids in the Jane and Terry Semel Institute for Neuroscience and Human Behavior and Professor in the UCLA Departments of Psychiatry and Biobehavioral Sciences and Anesthesiology.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT06859710
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated